Ultrasound Measurement of Vascular Density to Evaluate Response to Anti-Angiogenic Therapy in Renal Cell Carcinoma

<italic>Background:</italic> Functional and molecular changes often precede gross anatomical changes, so early assessment of a tumor's functional and molecular response to therapy can help reduce a patient's exposure to the side effects of ineffective chemotherapeutics or other treatment strategies. <italic>Objective:</italic> Our intent was to test the hypothesis that an ultrasound microvascular imaging approach might provide indications of response to therapy prior to assessment of tumor size. <italic>Methods:</italic> Mice bearing clear-cell renal cell carcinoma xenograft tumors were treated with antiangiogenic and Notch inhibition therapies. An ultrasound measurement of microvascular density was used to serially track the tumor response to therapy. <italic>Results:</italic> Data indicated that ultrasound-derived microvascular density can indicate response to therapy a week prior to changes in tumor volume and is strongly correlated with physiological characteristics of the tumors as measured by histology (<inline-formula><tex-math notation="LaTeX">$\rho = {\text{0.75}}$</tex-math></inline-formula>). Furthermore, data demonstrated that ultrasound measurements of vascular density can determine response to therapy and classify between-treatment groups with high sensitivity and specificity. <italic>Conclusion/Significance:</italic> Results suggests that future applications utilizing ultrasound imaging to monitor tumor response to therapy may be able to provide earlier insight into tumor behavior from metrics of microvascular density rather than anatomical tumor size measurements.

[1]  Vicky Goh,et al.  CT response assessment combining reduction in both size and arterial phase density correlates with time to progression in metastatic renal cancer patients treated with targeted therapies , 2010, Cancer biology & therapy.

[2]  Keith Flaherty,et al.  Clinical effect and future considerations for molecularly-targeted therapy in renal cell carcinoma. , 2008, Urologic oncology.

[3]  Paul A. Dayton,et al.  Early Assessment of Tumor Response to Radiation Therapy using High-Resolution Quantitative Microvascular Ultrasound Imaging , 2018, Theranostics.

[4]  Haesun Choi,et al.  We should desist using RECIST, at least in GIST. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[5]  Michael D. Abràmoff,et al.  Image processing with ImageJ , 2004 .

[6]  Mukund Seshadri,et al.  Dll4 Blockade Potentiates the Anti-Tumor Effects of VEGF Inhibition in Renal Cell Carcinoma Patient-Derived Xenografts , 2014, PloS one.

[7]  François Tranquart,et al.  Vascular endothelial growth factor receptor type 2-targeted contrast-enhanced US of pancreatic cancer neovasculature in a genetically engineered mouse model: potential for earlier detection. , 2015, Radiology.

[8]  J. Knox,et al.  Sunitinib in solid tumors , 2009, Expert opinion on investigational drugs.

[9]  Gabriele Bergers,et al.  Modes of resistance to anti-angiogenic therapy , 2008, Nature Reviews Cancer.

[10]  Fabio Cominelli,et al.  Targeting mucosal addressin cellular adhesion molecule (MAdCAM)-1 to noninvasively image experimental Crohn's disease. , 2006, Gastroenterology.

[11]  Michael B Atkins,et al.  Resistance to targeted therapy in renal-cell carcinoma. , 2009, The Lancet. Oncology.

[12]  Gavin Thurston,et al.  Blockade of Dll4 inhibits tumour growth by promoting non-productive angiogenesis , 2006, Nature.

[13]  B. Ariff,et al.  The role of early 18F-FDG PET/CT in prediction of progression-free survival after 90Y radioembolization: comparison with RECIST and tumour density criteria , 2012, European Journal of Nuclear Medicine and Molecular Imaging.

[14]  Paul A. Dayton,et al.  3-D Ultrasound Localization Microscopy for Identifying Microvascular Morphology Features of Tumor Angiogenesis at a Resolution Beyond the Diffraction Limit of Conventional Ultrasound , 2017, Theranostics.

[15]  Holger Gerhardt,et al.  Dll4 signalling through Notch1 regulates formation of tip cells during angiogenesis , 2007, Nature.

[16]  Paul A. Dayton,et al.  Ultrasound Molecular Imaging of VEGFR-2 in Clear-Cell Renal Cell Carcinoma Tracks Disease Response to Antiangiogenic and Notch-Inhibition Therapy , 2018, Theranostics.

[17]  M. Christian,et al.  [New guidelines to evaluate the response to treatment in solid tumors]. , 2000, Bulletin du cancer.

[18]  Sanjiv S Gambhir,et al.  Ultrasound Molecular Imaging With BR55 in Patients With Breast and Ovarian Lesions: First-in-Human Results. , 2017, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[19]  K. Cox,et al.  Contrast-Enhanced Ultrasound Biopsy of Sentinel Lymph Nodes in Patients with Breast Cancer: Implications for Axillary Metastases and Conservation , 2015, Annals of Surgical Oncology.

[20]  Paul A Dayton,et al.  Quantification of Microvascular Tortuosity during Tumor Evolution Using Acoustic Angiography. , 2015, Ultrasound in medicine & biology.

[21]  Haesun Choi,et al.  Correlation of computed tomography and positron emission tomography in patients with metastatic gastrointestinal stromal tumor treated at a single institution with imatinib mesylate: proposal of new computed tomography response criteria. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[22]  Dimitre Hristov,et al.  VEGFR2-Targeted Three-Dimensional Ultrasound Imaging Can Predict Responses to Antiangiogenic Therapy in Preclinical Models of Colon Cancer. , 2016, Cancer research.

[23]  Dimitre Hristov,et al.  Three-Dimensional Ultrasound Molecular Imaging of Angiogenesis in Colon Cancer Using a Clinical Matrix Array Ultrasound Transducer , 2015, Investigative radiology.

[24]  F. Stuart Foster,et al.  High Resolution Ultrasound Superharmonic Perfusion Imaging: In Vivo Feasibility and Quantification of Dynamic Contrast-Enhanced Acoustic Angiography , 2017, Annals of Biomedical Engineering.

[25]  Fabian Kiessling,et al.  Squamous Cell Carcinoma Xenografts: Use of VEGFR2-targeted Microbubbles for Combined Functional and Molecular US to Monitor Antiangiogenic Therapy Effects. , 2016, Radiology.

[26]  Kristina M. Cook,et al.  Angiogenesis Inhibitors: Current Strategies and Future Prospects , 2010, CA: a cancer journal for clinicians.

[27]  Paul A Dayton,et al.  Validation of dynamic contrast-enhanced ultrasound in rodent kidneys as an absolute quantitative method for measuring blood perfusion. , 2011, Ultrasound in medicine & biology.

[28]  Paul A Dayton,et al.  Quantitative Volumetric Perfusion Mapping of the Microvasculature Using Contrast Ultrasound , 2010, Investigative radiology.

[29]  Charles M. Perou Comprehensive molecular characterization of clear cell renal cell carcinoma , 2013 .

[30]  Wolfgang A Weber,et al.  Time course of tumor metabolic activity during chemoradiotherapy of esophageal squamous cell carcinoma and response to treatment. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[31]  Dimitre Hristov,et al.  Intra-Animal Comparison between Three-dimensional Molecularly Targeted US and Three-dimensional Dynamic Contrast-enhanced US for Early Antiangiogenic Treatment Assessment in Colon Cancer. , 2017, Radiology.

[32]  François Tranquart,et al.  First-in-Human Ultrasound Molecular Imaging With a VEGFR2-Specific Ultrasound Molecular Contrast Agent (BR55) in Prostate Cancer: A Safety and Feasibility Pilot Study , 2017, Investigative radiology.

[33]  M. Tanter,et al.  Ultrafast ultrasound localization microscopy for deep super-resolution vascular imaging , 2015, Nature.

[34]  Michael B Lawrence,et al.  Ultrasound-based molecular imaging and specific gene delivery to mesenteric vasculature by endothelial adhesion molecule targeted microbubbles in a mouse model of Crohn's disease. , 2013, Journal of controlled release : official journal of the Controlled Release Society.

[35]  Steven J. M. Jones,et al.  Comprehensive molecular characterization of clear cell renal cell carcinoma , 2013, Nature.

[36]  Minhong Yan,et al.  Inhibition of Dll4 signalling inhibits tumour growth by deregulating angiogenesis , 2006, Nature.

[37]  Apurva A Desai,et al.  Sorafenib in advanced clear-cell renal-cell carcinoma. , 2007, The New England journal of medicine.

[38]  Xin Huang,et al.  Overall Survival and Updated Results for Sunitinib Compared With Interferon Alfa in Patients With Metastatic Renal Cell Carcinoma , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[39]  R. Figlin,et al.  Activity of SU11248, a multitargeted inhibitor of vascular endothelial growth factor receptor and platelet-derived growth factor receptor, in patients with metastatic renal cell carcinoma. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[40]  Molly L Flexman,et al.  Contrast ultrasound imaging for identification of early responder tumor models to anti-angiogenic therapy. , 2012, Ultrasound in medicine & biology.

[41]  Ingrid Leguerney,et al.  Molecular ultrasound imaging using contrast agents targeting endoglin, vascular endothelial growth factor receptor 2 and integrin. , 2015, Ultrasound in medicine & biology.

[42]  F. Stuart Foster,et al.  Acoustic Angiography: A New Imaging Modality for Assessing Microvasculature Architecture , 2013, Int. J. Biomed. Imaging.

[43]  Linda Chami,et al.  Advanced hepatocellular carcinoma: early evaluation of response to bevacizumab therapy at dynamic contrast-enhanced US with quantification--preliminary results. , 2011, Radiology.

[44]  The Cancer Genome Atlas Research Network COMPREHENSIVE MOLECULAR CHARACTERIZATION OF CLEAR CELL RENAL CELL CARCINOMA , 2013, Nature.

[45]  Paul A Dayton,et al.  A Pilot Clinical Study in Characterization of Malignant Renal-cell Carcinoma Subtype with Contrast-enhanced Ultrasound , 2017, Ultrasonic imaging.

[46]  John C Chappell,et al.  Regulation of blood vessel sprouting. , 2011, Seminars in cell & developmental biology.

[47]  Nathalie Lassau,et al.  Advanced Hepatocellular Carcinoma: early evaluation of response to targeted therapy and prognostic value of Perfusion CT and Dynamic Contrast Enhanced-Ultrasound. Preliminary results. , 2013, European journal of radiology.

[48]  Seth M Steinberg,et al.  A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer. , 2003, The New England journal of medicine.

[49]  W. Kaelin,et al.  Molecular pathways in renal cell carcinoma--rationale for targeted treatment. , 2006, Seminars in oncology.

[50]  Dimitre Hristov,et al.  Early prediction of tumor response to bevacizumab treatment in murine colon cancer models using three-dimensional dynamic contrast-enhanced ultrasound imaging , 2017, Angiogenesis.

[51]  John C Chappell,et al.  Flt-1 (Vascular Endothelial Growth Factor Receptor-1) Is Essential for the Vascular Endothelial Growth Factor–Notch Feedback Loop During Angiogenesis , 2013, Arteriosclerosis, thrombosis, and vascular biology.

[52]  J Nuyts,et al.  18FDG-Positron emission tomography for the early prediction of response in advanced soft tissue sarcoma treated with imatinib mesylate (Glivec). , 2003, European journal of cancer.

[53]  Martijn R. Meijerink,et al.  Targeted therapies in renal cell cancer: recent developments in imaging , 2010, Targeted Oncology.

[54]  Paul A Dayton,et al.  A new preclinical ultrasound platform for widefield 3D imaging of rodents. , 2018, The Review of scientific instruments.

[55]  Mickael Tanter,et al.  Resolution limits of ultrafast ultrasound localization microscopy , 2015, Physics in medicine and biology.

[56]  Gavin Thurston,et al.  Dll4-Notch signaling as a therapeutic target in tumor angiogenesis , 2011, Vascular cell.

[57]  Jonathan R Lindner,et al.  Quantitative assessment of placental perfusion by contrast-enhanced ultrasound in macaques and human subjects. , 2016, American journal of obstetrics and gynecology.

[58]  Fabian Kiessling,et al.  Molecular and functional ultrasound imaging in differently aggressive breast cancer xenografts using two novel ultrasound contrast agents (BR55 and BR38) , 2011, European Radiology.

[59]  J. Yeh,et al.  A Comparative Evaluation of Ultrasound Molecular Imaging, Perfusion Imaging, and Volume Measurements in Evaluating Response to Therapy in Patient-Derived Xenografts , 2013, Technology in cancer research & treatment.

[60]  Linda Chami,et al.  To predict progression-free survival and overall survival in metastatic renal cancer treated with sorafenib: pilot study using dynamic contrast-enhanced Doppler ultrasound. , 2006, European journal of cancer.

[61]  Maximilian Reiser,et al.  Contrast-Enhanced Ultrasound with VEGFR2-Targeted Microbubbles for Monitoring Regorafenib Therapy Effects in Experimental Colorectal Adenocarcinomas in Rats with DCE-MRI and Immunohistochemical Validation , 2017, PloS one.

[62]  F. Stuart Foster,et al.  Microultrasound Molecular Imaging of Vascular Endothelial Growth Factor Receptor 2 in a Mouse Model of Tumor Angiogenesis , 2007, Molecular imaging.